结直肠癌警哨检测.pptVIP

* 大肠警哨（ColonSentry） 一项针对大肠癌的全新血液检测 全球首个用于大肠癌早期筛查的血液检测 上海分子医学工程技术研究中心 生物芯片上海国家工程研究中心 全球新癌症病例和死亡人数(GLOBOCAN) 发达国家 全球 新病例 死亡人数 Jemal et al., CA Cancer J Clin 2011; 61:69-90 中国结直肠癌发病率和死亡率 过去30年肿瘤5年总生存期延长缓慢 , Accessed July 21, 2011 诊断年份 % 0 5 10 15 20 1975 1985 1995 2005 结直肠癌病程进展 5年生存率 94% 82% 62% 8% 1-3 years to develop Early-Stage Cancer Late-Stage Cancer 60% of new cases 结直肠癌死亡原因 Fecal occult blood test (FOBT) and Fecal Immunicochemical Test (FIT) Repeats needed for reliable result Suboptimal performance Dietary medication restrictions Complicated multi-day procedure Poor patient compliance Colonoscopy Gold standard / standard of care Overkill: 90% negative Invasive with bowel prep Often involves sedation 1/100 result in complications1 1/10000 patients die2 * 现有结直肠癌筛查方法 Virtual Colonoscopy Medical imaging procedure using x-rays and computers Invasive with bowel prep Radiation from x-rays Polyps between 2 10mm may not show up in images 1. Leffler, Kheraj, et al, Arch Intern Med. (2010) 2. Pignone, M. and Rich, M., Annals of Internal Medicine 137.2 (2002) A blood test to pre-screen for CRC will help overcome current option limitations to facilitate higher rates of screening and earlier CRC detection. Fecal DNA test (coming in 2013) Requires handling of stool 什么是大肠警哨? Pre-screening test Assess patient’s current risk of having CRC now Determines if current risk is “increased”, average, or “decreased” relative to the general population. Encourage patient compliance with current CRC screening guidelines RNA test – not a Genetic test No Dietary restrictions No Bowel prep No Days off work No Sedation No Handling of feces or toilet water No Risk of bowel bleeding, perforation, infection, death Patient friendly Easily incorporated into routine health exam Non-invasive Minimal risk of complications Benefits 警哨原理: 筛选血液中肿瘤标志物新方法 Circulating blood reflects, in a detectable